Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PI4KA | P42356 | 4/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29877577 | 1.00 | CYP2C19 (0.55) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29878798 | 0.86 | YTHDC1 (0.45) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29878036 | 0.85 | YTHDC1 (0.46) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL114895 | 0.85 | YTHDC1 (0.46) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29877568 | 0.84 | CYP2C19 (0.56) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29877528 | 0.83 | CYP2C19 (0.55) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16139202 | 0.83 | NPC1 (0.40) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30078296 | 0.83 | PI4KA (0.53) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14964635 | 0.83 | PI4KA (0.60) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29877634 | 0.82 | CYP2C19 (0.56) | CYP2C19PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2023183444-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2022178256-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11339163-B2 | BRaf inhibitors and use thereof for treatment of cutaneous reactions | LUTRIS PHARMA LTD. (IL) | 2022-05-24 | — | — | US | disclosed |
| EP-3412670-B1 | PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2022-03-09 | — | — | EP | disclosed |
| EP-3661515-B1 | NOVEL BRAF INHIBITORS AND USE THEREOF FOR TREATMENT OF CUTANEOUS REACTIONS | LUTRIS PHARMA LTD (IL) | 2022-02-23 | — | — | EP | disclosed |
| CN-109071543-B | Pyridine derivatives inhibiting RAF kinase and vascular endothelial growth factor receptor, process for their preparation, pharmaceutical compositions containing them and their use | 三进制药株式会社 | 2021-07-16 | — | — | CN | disclosed |
| US-20210070757-A1 | BRAF INHIBITORS AND USE THEREOF FOR TREATMENT OF CUTANEOUS REACTIONS | LUTRIS PHARMA LTD (IL) | 2021-03-11 | — | — | US | disclosed |
| US-10927112-B2 | BRaf inhibitors and use thereof for treatment of cutaneous reactions | LUTRIS PHARMA LTD. (IL) | 2021-02-23 | — | — | US | disclosed |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2170887-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | Amgen Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008153947-A2 | HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | CYP2C19 1960/4885PI4KA 23/4885PI4K2B 71/4885 |
| US-11339163-B2 | BRaf inhibitors and use thereof for treatment of cutaneous reactions | BRAF, NRAS, PIK3C3 | CYP2C19 811/4885PI4KA 163/4885PI4K2B 281/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | CYP2C19 355/4885PI4KA 238/4885PI4K2B 395/4885 |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | TYMP, DPYD, PNP | CYP2C19 195/4885PI4KA 1412/4885PI4K2B 1078/4885 |
| US-10927112-B2 | BRaf inhibitors and use thereof for treatment of cutaneous reactions | BRAF, NRAS, RAF1 | CYP2C19 475/4885PI4KA 231/4885PI4K2B 354/4885 |
| US-20210070757-A1 | BRAF INHIBITORS AND USE THEREOF FOR TREATMENT OF CUTANEOUS REACTIONS | BRAF, NRAS, PIK3C3 | CYP2C19 811/4885PI4KA 163/4885PI4K2B 281/4885 |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | BRAF, KDR, RAF1 | CYP2C19 2208/4885PI4KA 449/4885PI4K2B 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.